The effect of HbA1c variability on outcomes, including mortality, myocardial infarction, and stroke, appeared to be independent of directional trends or baseline HbA1c level.
Incretin-based drugs not associated with higher risk of pancreatitis in large, population-based study
The findings of this study should provide some reassurance to patients treated with incretin-based drugs, according to the authors.
Patients with type 2 diabetes and a systolic blood pressure of 110 to 119 mm Hg appeared to have a lower risk of cardiovascular disease than patients who had systolic blood pressures of 130 to 139 mm Hg, according to a registry study.
This month's quiz asks readers to evaluate a 51-year-old man who was recently diagnosed with hypertension and diabetes mellitus.
Taking canagliflozin, at a dose of either 100 mg or 300 mg per day, was associated with risk of diabetic ketoacidosis, according to a trial that randomized patients with type 1 diabetes to either of the doses or a placebo.
Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations
Incretin-based drugs did not appear to be associated with greater heart failure hospitalization risk compared with commonly used combinations of oral antidiabetic drugs, a cohort study found.
Current use of DPP-4 inhibitors was not associated with increased risk for bile duct and gallbladder disease versus current use of at least 2 oral antidiabetic drugs, but an increased risk was seen with use of GLP-1 analogues.
Lixisenatide (Adlyxin), a once-daily injection, was approved by the FDA on July 28 to improve glycemic control in adults with type 2 diabetes.